Myriad Grows Internationally, Hereditary Cancer Revenues Soft
Zacks Investment Research | Mar 18, 2020 09:46PM ET
On Mar 18, we issued an updated research report on Myriad Genetics, Inc. (NASDAQ:MYGN) . The company is making significant progress in its portfolio expansion. Emerging competitors and pricing pressure might prove detrimental to Myriad’s stock in the near future. The stock carries a Zacks Rank #4 (Sell), at present.
Of late, within companion diagnostics, the company has been witnessing significant progress with both BRACAnalysis CDx and myChoice CDx. Last December, the company attained FDA approval for BRACAnalysis CDx in pancreatic cancer. Around the same time, it received the FDA’s nod for myChoice CDx as the companion diagnostic in ovarian cancer patients.
This January, the company submitted its application for BRACAnalysis CDx in castrate resistant metastatic prostate cancer, with the FDA approval anticipated to come in the latter half of fiscal 2020. These developments are expected to result in a clinical impetus for patients of these two cancer types, which comprise approximately 90,000 incident patients in the United States per year.
Fortifying its global foothold, the company has been receiving encouraging response for BRACAnalysis CDx in Japan for metastatic breast cancer. In this regard, the company has received Japan’s approval for BRACAnalysis CDx as the companion diagnostic in first line ovarian cancer with olaparib. The company is optimistic about the scope of this test in Japan based on the fact that every year roughly 22,000 cancer patients in Japan are eligible for companion diagnostic testing. The company also recently filed for the regulatory approval of myChoice CDx in Japan for its potential use in ovarian cancer, which comprises approximately 9000 patients per year.
Myriad Genetics has, so far, made a significant progress with its five strategic imperatives that include transition and expansion of the hereditary cancer market, diversifying revenues by commercializing its new products, ramping up the company’s international contribution by investing in large countries, gaining reimbursement for the launched products, increasing international RNA kit revenues and enhancing profitability with Elevate 2020. It is important to note here that the Elevate 2020 program — introduced by Myriad Genetics — targets $50 million in incremental operating income by fiscal 2020.
However, Myriad Genetics witnessed a decline in Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020. Management is anticipating a $10-million sequential decline in hereditary cancer revenues due to seasonality and PAMA. The company incurred operating loss during the quarter. The slashed fiscal 2020 guidance indicates continuation of this sluggish trend. Foreign-exchange headwinds and escalating expenses continue to be dampeners.
Shares of this Salt Lake City, UT-based molecular diagnostics provider have underperformed the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.